Unlocking the complexities of cancer biology with BOND RX and Ultivue.
Melbourne, Australia and Cambridge, Massachusetts – September 14, 2018 | Leica Biosystems and Ultivue begin Co-Marketing of UltiMapper™ Assay on the BOND RX enabling single-step automated multiplexing in under 6 hours.
Building on its legacy of partnering with emerging technology leaders, Leica Biosystems have partnered with Ultivue and announced the co-marketing of Ultivue’s UltiMapper™ assays with Leica Biosystems’ BOND RX research staining platform1 enabling rapid automated multiplex biomarker detection.
The Ultivue UltiMapper single step multiplexing assay is pre-optimized for the BOND RX enabling a fully automated plug-and-play solution resulting in the creation of 30, five color, high performance immunohistochemistry multiplexing slides in under 6 hours while preserving tissue morphology and integrity. Ultivue’s unique DNA barcode attached to each antibody allows all antibodies to be stained in a single step, taking the typical multi-day manual multiplex test and transforming it into a process that can fit into a standard workday. UltiMapper and BOND RX perfectly complement one another, freeing up researchers’ time from perfecting difficult manual techniques, allowing them to focus on analyzing the results.
Leica Biosystems offers researchers the opportunity of a complete end-to-end workflow solution. Automated staining of the UltiMapper assay on the BOND RX and slide scanning and quantification using the Aperio VERSA fluorescence tissue scanner and Aperio Cellular IF Algorithm2 brings new technologies to more researchers.
“With tissue sample sizes decreasing, and scientific advancements expanding the number of actionable biomarkers, multiplexing is an increasingly common technique used by researchers to explore complex biology” said Colin White PhD, Global Vice President of Advanced Staining at Leica Biosystems. “We are very pleased to be able to offer investigators an automated version of Ultivue’s UltiMapper multiplexing technology on the BOND RX thereby supporting research excellence through workflow efficiency and stain consistency”.
“We are delighted to partner with Leica Biosystems to bring to the Research market, a complete automated solution to realize the full potential of tissue-based, multiplexed marker studies at high throughput,” said Philippe Mourere, Senior Vice President of Commercial Operations at Ultivue. “Through our growing immuno-oncology portfolio of kits and assays, translational and clinical researchers have immediate access to unbiased biology with the ability to co-localize markers on single cells, and to functionally characterize cellular interactions within the tumor microenvironment. Looking ahead, we are expanding our level of multiplexing and widening our content offering to adjacent research areas.”
1. FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES
2. Other whole slide imaging and analysis options are available
About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in workflow solutions. Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our experts are committed to delivering Improved Quality, Integrated Solutions, and Optimized Efficiencies leading to breakthrough advances in diagnostic confidence. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. The company is headquartered in Germany and operates in over 100 countries with manufacturing facilities in 9 countries. Visit LeicaBiosystems.com for more information.
Multiplexed biomarker assays in tissue for personalized medicine research and clinical pathology.
By developing a single set of novel, proprietary reagents used both for biomarker discovery (higher content, low throughput) and clinical use (lower content, high throughput), Ultivue is connecting the insights gained from research directly into the pathology lab. Ultivue’s UltiMapper™ multiplexed assays applied to tissue biopsy samples enable simultaneous quantitation of multiple biomarkers with sub-cellular spatial resolution and fit completely within traditional IHC workflows. Translational and clinical researchers leverage UltiMapper™ assays to elucidate complex biology and demonstrate their clinical utility as precision medicine tools. Ultivue is expanding its UltiMapper™ assay product portfolio and menu of contract research services to provide a comprehensive set of personalized medicine solutions for oncology and other therapeutic areas.
Ultivue is based in Cambridge, MA. For more information, visit Ultivue.com